U.S. Markets open in 1 hr 58 mins

Aurinia Pharmaceuticals (AUPH) in Focus: Stock Moves 6.7% Higher

Zacks Equity Research
1 / 2

Will Product Innovations Aid Canopy Growth (CGC) in Q2?

Canopy Growth (CGC) is expected to benefit from a solid top-line contribution in the Canadian medical cannabis market.

Aurinia Pharmaceuticals Inc. AUPH was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $5.37 to $6.10 in the past one-month time frame.

The company has seen no changes when it comes to estimate revision over the past month, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Aurinia Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.  

Aurinia Pharmaceuticals Inc Price

Aurinia Pharmaceuticals Inc Price | Aurinia Pharmaceuticals Inc Quote

A better-ranked stock in the Medical – Drugs industry is Pacira Pharmaceuticals, Inc. PCRX, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is AUPH going up? Or down? Predict to see what others think: Up or Down

Wall Street’s Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>

 


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Pacira Pharmaceuticals, Inc. (PCRX) : Free Stock Analysis Report
 
Aurinia Pharmaceuticals Inc (AUPH) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research